Stay updated with breaking news from David Spigel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years Longest-ever survival reported in a Phase III immunotherapy trial in this setting ...
Date Time Share Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer with 43% of patients surviving five years Updated results from the positive PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT). Lung cancer is the leading cause of cancer death accounting for about one-fif...
119 Abstracts and Presentations Featuring Sarah Cannon's Clinical Research and Care Insights Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society
Sarah Cannon has announced the promotion of Dr. Melissa Johnson to program director of lung cancer research. Since joining Nashville-based Sarah Cannon in 2014, Johnson (pictured) has served as the associate director of lung cancer research at Sarah Cannon Research Institute (the research arm of Sarah Cannon), supporting the growth of early-phase compounds in thoracic malignancies. In her new role, she will lead the lung cancer clinical trial portfolio across the Sarah Cannon network. Johnson will continue to work in early-phase drug development as well as lead the solid tumor immune effector...
Press release content from Business Wire. The AP news staff was not involved in its creation. Sarah Cannon Promotes Melissa Johnson, MD, to Program Director, Lung Cancer Research December 17, 2020 GMT NASHVILLE, Tenn.--(BUSINESS WIRE)--Dec 17, 2020-- Today, Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research. In her new role, Dr. Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network. “Since joining Sarah Cannon, Dr. Johnson’s contributions to research have helped transform the treatment options avail...